Eli Lilly and Company - Net Income From Continuing Operations

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Net-Income-From-Continuing-Operations" stands at 18.41 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 5.58 Billion USD for the item "Net Income From Continuing Operations" represents a decrease of -1.38 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 5.58 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 475.34 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 18.41 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 33.42 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 10.04 Billion United States Dollars compared to the value the year prior.
The 1 year change is 10.04 Billion United States Dollars.
The 3 year change is 12.38 Billion United States Dollars.
The 5 year change is 12.84 Billion United States Dollars.
The 10 year change is 15.42 Billion United States Dollars.

The Serie's long term average value is 4.45 Billion United States Dollars. It's latest available value, on 09/30/2025, is 13.97 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 12/31/2017, to it's latest available value, on 09/30/2025, is +18.62 Billion.
The Serie's change in United States Dollars from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0 Billion.